文献速递肝肾功能剂量调整治疗药物监测与药物基因组学

重型颅脑损伤与蛛网膜下腔出血患者左乙拉西坦群体药代动力学及肾功能增强清除影响

Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance.
PubMed 文献 · Clin Pharmacokinet · 2021-01-11

本研究在30例重型颅脑损伤或动脉瘤性蛛网膜下腔出血成人患者中建立左乙拉西坦二室群体药代动力学模型,发现尿肌酐清除率每增加40 mL/min/1.73 m²,中位谷浓度平均降低50%,部分肾功能增强清除患者需至少6 g/日剂量才能达标。

要点

  • 肾功能增强清除患者左乙拉西坦谷浓度显著降低,癫痫预防失败风险增加。
  • 尿肌酐清除率每升高40 mL/min/1.73 m²,中位谷浓度平均下降50%。
  • 建议根据实测肌酐清除率滴定剂量,有条件时进行治疗药物监测。

核心结论

  • 重型颅脑损伤和动脉瘤性蛛网膜下腔出血伴肾功能增强清除的患者存在左乙拉西坦血浆浓度不达标风险。
  • 建议依据实测肌酐清除率进行剂量滴定,有条件时结合治疗药物监测,以降低癫痫发作风险。

研究设计与样本

  • 前瞻性开放标签观察性研究,纳入30例无肾功能不全且接受左乙拉西坦治疗的重型颅脑损伤或动脉瘤性蛛网膜下腔出血成人患者。
  • 采集系列左乙拉西坦血浆浓度,建立群体药代动力学模型并进行给药方案模拟。

主要发现

  • 二室模型最佳描述浓度-时间数据,生物利用度为0.8 ± 0.2,吸收速率常数为2.4 ± 2 h⁻¹。
  • 清除率为2.5 ± 1.1 L/h,中央室分布容积为8.9 ± 3.0 L/h(原文单位),中央至外周转移速率常数为1.8 ± 1.1 h⁻¹,外周至中央为0.7 ± 0.3 h⁻¹。
  • 模拟间歇给药方案中,尿肌酐清除率每增加40 mL/min/1.73 m²,中位谷浓度平均降低50%。
  • 部分肾功能增强清除水平下,模拟所需剂量至少为6 g/日。

临床怎么用

  • 对重型颅脑损伤或动脉瘤性蛛网膜下腔出血伴肾功能增强清除的患者,应关注左乙拉西坦浓度不达标风险。
  • 可依据实测肌酐清除率调整左乙拉西坦剂量,有条件时开展治疗药物监测指导个体化给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Patients with severe trauma exhibit augmented renal clearance, which can alter the dosing requirement of renally eliminated drugs. This study aimed to develop a population pharmacokinetic model for levetiracetam in patients with severe traumatic brain injury and aneurysmal subarachnoid hemorrhage, and use it to describe optimal dosing regimens. METHODS: This was a prospective open-label observational study. Critically ill adult patients with severe traumatic brain injury or aneurysmal subarachnoid hemorrhage without renal dysfunction and receiving levetiracetam were eligible. Serial levetiracetam plasma concentrations were analyzed to develop a population pharmacokinetic model and perform dosing simulations. RESULTS: A two-compartment model best described the concentration-time data from 30 patients. The mean ± standard deviation parameter estimates were bioavailability (F) of 0.8 ± 0.2, absorption rate constant of 2.4 ± 2 h-1, clearance 2.5 ± 1.1 L/h, central volume of distribution 8.9 ± 3.0 L/h, and transfer rate constraints of 1.8 ± 1.1 h-1 from central to peripheral compartments and 0.7 ± 0.3 h-1 from peripheral to central compartments. For the simulated intermittent dosing regimens, on average, the median trough concentration reduced by 50% for every 40-mL/min/1.73 m2 increase in urinary creatinine clearance. Simulated doses of at least 6 g/day were required for some levels of augmented renal clearance. CONCLUSIONS: Patients with severe traumatic brain injury and aneurysmal subarachnoid hemorrhage with augmented renal clearance are at risk of not achieving target levetiracetam plasma concentrations. We suggest dose titration guided by measured creatinine clearance, and/or, therapeutic drug monitoring if available, to minimize the risk of seizures.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Sime FB, Roberts JA, Jeffree RL, et al. Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. Clin Pharmacokinet. 2021. PMID: 33428169. doi:10.1007/s40262-020-00979-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。